Chronic hemolysis following mitral valve replacement. A comparative study of the Björk-Shiley, composite-seat Starr-Edwards, and frame-mounted aortic homograft valves.
Hemolysis was assessed in 86 patients after mitral valve replacement. Twenty-four patients had mitral valve replacement with a Björk-Shiley valve, 32 patients with a Starr-Edwards composite-seat valve, and 30 patients with an irradiated frame-mounted aortic homograft valve. Hemolysis was determined by red cell survival and autologous 51Cr-tagged red cells, LDH, serum haptoglobin, hemosiderinuria, reticulocyte count, red cell fragment count, and hemoglobin estimation. The degree of hemolysis was classified as mild, moderate, or severe. Thirty-five per cent (nine of 24) of the Björk-Shiley group showed mild hemolysis, whereas 85 per cent (28 of 32) of the Starr-Edwards group had evidence of hemolysis-of these, a third were mild and the rest moderate. The homograft series did not show any comparable evidence of hemolysis. Statistical analysis of the parameters of the study comparing homograft with Björk-Shiley valves showed no significant difference except in red cell survival, which showed a highly significant difference (p less than 0.001). Comparing homograft with Starr-Edwards valves, all parameters showed highly significant differences (p less than 0.001).
D000743:Anemia, Hemolytic / Q000209:etiology*; D001772:Blood Cell Count; D002860:Chromium Radioisotopes; D002908:Chronic Disease; D005260:Female; D006242:Haptoglobins; D006350:Heart Valve Prosthesis / Q000009:adverse effects*; D006452:Hemoglobinometry; D006461:Hemolysis; D006485:Hemosiderin / Q000652:urine; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D008943:Mitral Valve / Q000601:surgery*
D002860:Chromium Radioisotopes; D006242:Haptoglobins; D006485:Hemosiderin; D007770:L-Lactate Dehydrogenase